Trelagliptin Succinate
Glycemic control in type 2 diabetes (once-weekly oral)
- CAS No.
- 1029877-94-8
- Indication Class
- Metabolic / Endocrine
- Patent Expiry
- To be assessed
- Therapeutic Area
- Endocrine / Metabolism
- Target / Mechanism
- DPP4
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- Candidate (In-research)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
The world's first once-weekly oral DPP-4 inhibitor, markedly improving adherence; suited to fixed-dose combination with metformin and aligned with chronic-disease management policy.
Endocrine / Metabolism · In research; suited to co-development
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Trelagliptin Succinate is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting this enzyme to increase the level of incretin hormones in the body, thereby promoting insulin secretion and lowering blood glucose for the treatment of type 2 diabetes. Its most notable feature is an ultra-long duration of action, allowing for once-weekly oral dosing, which significantly enhances patient convenience and medication adherence.
Supply source: Unibest · Trelagliptin Succinate, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.